
ExpreS²ion's CEO in interview on 2019 and the company's new way forward with a stronger pipeline focus

ExpreS²ion Biotech Holding AB ("ExpreS²ion") publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company's new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS² platform.

The CEO interview is available via this link: <https://mailchi.mp/expres2ionbio.com/january2020>

This interview is a part of ExpreS²ion's efforts to improve its communication with shareholders and others interested in the company in 2020 and thereafter.

For additional information, please contact

ExpreS²ion Biotech Holding AB
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
E-mail: ca@skmg.se

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatory validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.